Materias dentro de su búsqueda.
Mostrando 1,551,661 - 1,551,680 Resultados de 1,551,782 Para Buscar '"The Associate"', tiempo de consulta: 9.07s Limitar resultados
  1. 1551661
    por Pastorello, Gilberto, Trotta, Carlo, Canfora, Eleonora, Chu, Housen, Christianson, Danielle, Cheah, You-Wei, Poindexter, Cristina, Chen, Jiquan, Elbashandy, Abdelrahman, Humphrey, Marty, Isaac, Peter, Polidori, Diego, Ribeca, Alessio, van Ingen, Catharine, Zhang, Leiming, Amiro, Brian, Ammann, Christof, Arain, M. Altaf, Ardö, Jonas, Arkebauer, Timothy, Arndt, Stefan K., Arriga, Nicola, Aubinet, Marc, Aurela, Mika, Baldocchi, Dennis, Barr, Alan, Beamesderfer, Eric, Marchesini, Luca Belelli, Bergeron, Onil, Beringer, Jason, Bernhofer, Christian, Berveiller, Daniel, Billesbach, Dave, Black, Thomas Andrew, Blanken, Peter D., Bohrer, Gil, Boike, Julia, Bolstad, Paul V., Bonal, Damien, Bonnefond, Jean-Marc, Bowling, David R., Bracho, Rosvel, Brodeur, Jason, Brümmer, Christian, Buchmann, Nina, Burban, Benoit, Burns, Sean P., Buysse, Pauline, Cale, Peter, Cavagna, Mauro, Cellier, Pierre, Chen, Shiping, Chini, Isaac, Christensen, Torben R., Cleverly, James, Collalti, Alessio, Consalvo, Claudia, Cook, Bruce D., Cook, David, Coursolle, Carole, Cremonese, Edoardo, Curtis, Peter S., D’Andrea, Ettore, da Rocha, Humberto, Dai, Xiaoqin, Davis, Kenneth J., De Cinti, Bruno, de Grandcourt, Agnes, De Ligne, Anne, De Oliveira, Raimundo C., Delpierre, Nicolas, Desai, Ankur R., Di Bella, Carlos Marcelo, di Tommasi, Paul, Dolman, Han, Domingo, Francisco, Dong, Gang, Dore, Sabina, Duce, Pierpaolo, Dufrêne, Eric, Dunn, Allison, Dušek, Jiří, Eamus, Derek, Eichelmann, Uwe, ElKhidir, Hatim Abdalla M., Eugster, Werner, Ewenz, Cacilia M., Ewers, Brent, Famulari, Daniela, Fares, Silvano, Feigenwinter, Iris, Feitz, Andrew, Fensholt, Rasmus, Filippa, Gianluca, Fischer, Marc, Frank, John, Galvagno, Marta, Gharun, Mana, Gianelle, Damiano, Gielen, Bert, Gioli, Beniamino, Gitelson, Anatoly, Goded, Ignacio, Goeckede, Mathias, Goldstein, Allen H., Gough, Christopher M., Goulden, Michael L., Graf, Alexander, Griebel, Anne, Gruening, Carsten, Grünwald, Thomas, Hammerle, Albin, Han, Shijie, Han, Xingguo, Hansen, Birger Ulf, Hanson, Chad, Hatakka, Juha, He, Yongtao, Hehn, Markus, Heinesch, Bernard, Hinko-Najera, Nina, Hörtnagl, Lukas, Hutley, Lindsay, Ibrom, Andreas, Ikawa, Hiroki, Jackowicz-Korczynski, Marcin, Janouš, Dalibor, Jans, Wilma, Jassal, Rachhpal, Jiang, Shicheng, Kato, Tomomichi, Khomik, Myroslava, Klatt, Janina, Knohl, Alexander, Knox, Sara, Kobayashi, Hideki, Koerber, Georgia, Kolle, Olaf, Kosugi, Yoshiko, Kotani, Ayumi, Kowalski, Andrew, Kruijt, Bart, Kurbatova, Julia, Kutsch, Werner L., Kwon, Hyojung, Launiainen, Samuli, Laurila, Tuomas, Law, Bev, Leuning, Ray, Li, Yingnian, Liddell, Michael, Limousin, Jean-Marc, Lion, Marryanna, Liska, Adam J., Lohila, Annalea, López-Ballesteros, Ana, López-Blanco, Efrén, Loubet, Benjamin, Loustau, Denis, Lucas-Moffat, Antje, Lüers, Johannes, Ma, Siyan, Macfarlane, Craig, Magliulo, Vincenzo, Maier, Regine, Mammarella, Ivan, Manca, Giovanni, Marcolla, Barbara, Margolis, Hank A., Marras, Serena, Massman, William, Mastepanov, Mikhail, Matamala, Roser, Matthes, Jaclyn Hatala, Mazzenga, Francesco, McCaughey, Harry, McHugh, Ian, McMillan, Andrew M. S., Merbold, Lutz, Meyer, Wayne, Meyers, Tilden, Miller, Scott D., Minerbi, Stefano, Moderow, Uta, Monson, Russell K., Montagnani, Leonardo, Moore, Caitlin E., Moors, Eddy, Moreaux, Virginie, Moureaux, Christine, Munger, J. William, Nakai, Taro, Neirynck, Johan, Nesic, Zoran, Nicolini, Giacomo, Noormets, Asko, Northwood, Matthew, Nosetto, Marcelo, Nouvellon, Yann, Novick, Kimberly, Oechel, Walter, Olesen, Jørgen Eivind, Ourcival, Jean-Marc, Papuga, Shirley A., Parmentier, Frans-Jan, Paul-Limoges, Eugenie, Pavelka, Marian, Peichl, Matthias, Pendall, Elise, Phillips, Richard P., Pilegaard, Kim, Pirk, Norbert, Posse, Gabriela, Powell, Thomas, Prasse, Heiko, Prober, Suzanne M., Rambal, Serge, Rannik, Üllar, Raz-Yaseef, Naama, Reed, David, de Dios, Victor Resco, Restrepo-Coupe, Natalia, Reverter, Borja R., Roland, Marilyn, Sabbatini, Simone, Sachs, Torsten, Saleska, Scott R., Sánchez-Cañete, Enrique P., Sanchez-Mejia, Zulia M., Schmid, Hans Peter, Schmidt, Marius, Schneider, Karl, Schrader, Frederik, Schroder, Ivan, Scott, Russell L., Sedlák, Pavel, Serrano-Ortíz, Penélope, Shao, Changliang, Shi, Peili, Shironya, Ivan, Siebicke, Lukas, Šigut, Ladislav, Silberstein, Richard, Sirca, Costantino, Spano, Donatella, Steinbrecher, Rainer, Stevens, Robert M., Sturtevant, Cove, Suyker, Andy, Tagesson, Torbern, Takanashi, Satoru, Tang, Yanhong, Tapper, Nigel, Thom, Jonathan, Tiedemann, Frank, Tomassucci, Michele, Tuovinen, Juha-Pekka, Urbanski, Shawn, Valentini, Riccardo, van der Molen, Michiel, van Gorsel, Eva, van Huissteden, Ko, Varlagin, Andrej, Verfaillie, Joseph, Vesala, Timo, Vincke, Caroline, Vitale, Domenico, Vygodskaya, Natalia, Walker, Jeffrey P., Walter-Shea, Elizabeth, Wang, Huimin, Weber, Robin, Westermann, Sebastian, Wille, Christian, Wofsy, Steven, Wohlfahrt, Georg, Wolf, Sebastian, Woodgate, William, Li, Yuelin, Zampedri, Roberto, Zhang, Junhui, Zhou, Guoyi, Zona, Donatella, Agarwal, Deb, Biraud, Sebastien, Torn, Margaret, Papale, Dario
    Publicado 2020
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The FLUXNET2015 dataset and the ONEFlux processing pipeline for eddy covariance data
  2. 1551662
    “…PK/PD/Immunogenicity • Change in serum ravulizumab concentrations over time • Change in serum free and total C5 concentrations over time • Incidence and titer of anti-ALXN1210 antibodies Biomarkers • Change in absolute level of soluble biomarkers in blood associated with complement activation, inflammatory processes, and hypercoagulable states over time Exploratory • Incidence of progression to renal failure requiring dialysis at Day 29 • Time to clinical improvement (based on a modified 6-point ordinal scale) over 29 days • SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores at Day 29 (or discharge), Day 60, and Day 90 • EuroQol 5-dimension 5-level (EQ-5D-5L) scores at Day 29 (or discharge), Day 60, and Day 90 TRIAL DESIGN: This is a multicenter Phase 3, open-label, randomized, controlled, study. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial
  3. 1551663
    “…Exhibiting symptoms associated with COVID-19 3. Positive for SARS-CoV-2 on valid COVID-19 test 4. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial
  4. 1551664
    “…DISCLOSURES: Danila Seidel, PhD, Basilea (Other Financial or Material Support, travel grant) Oliver Cornely, Prof., Actelion (Grant/Research Support)Actelion (Other Financial or Material Support, Personal fees)Al Jazeera Pharmaceuticals (Consultant)Allecra Therapeutics (Other Financial or Material Support, Personal fees)Amplyx (Other Financial or Material Support, Personal fees)Amplyx (Grant/Research Support)Astellas (Grant/Research Support)Astellas (Other Financial or Material Support, Personal fees)Basilea (Other Financial or Material Support, Personal fees)Basilea (Grant/Research Support)Biosys UK Limited (Other Financial or Material Support, Personal fees)Cidara (Other Financial or Material Support, Personal fees)Cidara (Grant/Research Support)Da Volterra (Grant/Research Support)Da Volterra (Other Financial or Material Support, Personal fees)Entasis (Other Financial or Material Support, Personal fees)F2G (Other Financial or Material Support)F2G (Grant/Research Support)Gilead (Grant/Research Support)Gilead (Other Financial or Material Support, Personal fees)Grupo Biotoscana (Other Financial or Material Support, Personal fees)Janssen Pharmaceuticals (Grant/Research Support)Matinas (Other Financial or Material Support, Personal fees)Medicines Company (Grant/Research Support)MedPace (Grant/Research Support)MedPace (Other Financial or Material Support, Personal fees)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche (Other Financial or Material Support, Personal fees)Merck/MSD (Other Financial or Material Support, Personal fees)Merck/MSD (Grant/Research Support)Mylan Pharmaceuticals (Consultant)Nabriva Therapeutics (Other Financial or Material Support, Personal fees)Octapharma (Other Financial or Material Support, Personal fees)Paratek Pharmaceuticals (Other Financial or Material Support, Personal fees)Pfizer (Other Financial or Material Support, Personal fees)Pfizer (Grant/Research Support)PSI (Other Financial or Material Support, Personal fees)Rempex (Other Financial or Material Support, Personal fees)Roche Diagnostics (Other Financial or Material Support, Personal fees)Scynexis (Other Financial or Material Support, Personal fees)Scynexis (Grant/Research Support)Seres Therapeutics (Other Financial or Material Support, Personal fees)Tetraphase (Other Financial or Material Support, Personal fees) Philipp Koehler, MD, Akademie für Infektionsmedizin e.V., (Other Financial or Material Support, Personal fees)Astellas Pharma GmbH (Other Financial or Material Support, Personal fees)Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany (Other Financial or Material Support, Other)Gilead Sciences GmbH (Other Financial or Material Support, Personal fees)GPR Academy Ruesselsheim (Speaker’s Bureau)Miltenyi Biotec GmbH (Other Financial or Material Support, Non-financial support)MSD Sharp & Dohme GmbH (Other Financial or Material Support, Personal fees)Noxxon N.V. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1172. Mucormycosis Treated with Isavuconazole: A matched-Pair Analysis from the FungiScope(®) Registry
  5. 1551665
    “…INTERVENTION AND COMPARATOR: RUXOLITINIB (RUX) (14 days): An oral selective and potent inhibitor of Janus Associated Kinases (JAK1 and JAK2) and cell proliferation (Verstovek, 2010). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial
  6. 1551666
    “…Secondary outcomes The included studies have data on (1) support‐surface‐associated patient comfort for comparisons involving foam surfaces, reactive air surfaces, reactive fibre surfaces and alternating pressure (active) air surfaces; (2) adverse events for comparisons involving foam surfaces, reactive gel surfaces and alternating pressure (active) air surfaces; and (3) health‐related quality of life outcomes for the comparison involving foam surfaces. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Alternating pressure (active) air surfaces for preventing pressure ulcers
  7. 1551667
    “…Secondary outcomes Support‐surface‐associated patient comfort: the review contains data for three comparisons for this outcome. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Foam surfaces for preventing pressure ulcers
  8. 1551668
    “…De même, les délais de survie n’étaient pas associés à la période SF0–J0. Un débit d’O2 à J0 > 12 L/min versus 4-8L/min (OR 9,73, IC à 95 % [2,10-45,12] ; HR 5,20, IC à 95 % [1,62–16,67]) était significativement associée au décès chez les patients traités par TCZ, alors que le taux de CRP à J0 ne l’était pas. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tocilizumab au cours du COVID-19 : le plus tôt serait le mieux ? Une analyse exploratoire de cohorte
  9. 1551669
    “…Currently, the mortality rate from COVID-19 in evaluable CML patients is 13.7%. Factors associated with a higher mortality rate are age and imatinib therapy. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
  10. 1551670
    “…In the multivariate logistic regression analysis examining associations between individual symptoms and antibody levels, there was strong correlation between anti-SARS-CoV-2 antibodies and anosmia (OR 11.14, 95% CI:3.92-31.67; p<0.001), loss of taste (OR 5.50, 95% CI:2.23-13.56; p<0.001), fever (OR 4.25, 95% CI:1.90-9.51; p<0.001), and headache (OR 2.34, 95% CI:1.09-5.03; p=0.029). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study
  11. 1551671
    “…Given the sensitivity and stigma associated with sexual and reproductive health future studies should measure unintended consequences, such as partner violence or breaches of confidentiality.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeted client communication via mobile devices for improving sexual and reproductive health
  12. 1551672
    “…Secondary objective To summarize the risk of drug‐associated adverse effects following MDA. SEARCH METHODS: We searched several trial registries, citation databases, conference proceedings, and reference lists for relevant articles up to 11 February 2021. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Mass drug administration for malaria
  13. 1551673
    “…RUX is an oral Janus Associated Kinase (JAK1/JAK2) inhibitor approved for the treatment of splenomegaly, myelofibrosis and polycythaemia vera. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial
  14. 1551674
    “…Methods Data were collected using the ITP COVID-19 web-based survey that is part of the Platelet Disorder Support Association's ITP Natural History Study Patient Registry. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Do Splenectomized Immune Thrombocytopenia (ITP) Patients Have Increased Risks for Platelet Decreases Following COVID-19 Vaccination?
  15. 1551675
    “…Primary and secondary endpoints of this study are the rate of acute respiratory distress syndrome (ARDS) and virus-associated 30- and 90-day mortalities. The retrospective data collection was performed in accordance with local legal requirements and was reviewed and approved by the Ethics Committee of the Medical Council of Hamburg. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Comparative Outcome Analysis of COVID-19 and Influenza Infection in Patients with Hematological Malignancies
  16. 1551676
    “…Venetoclax based, and other non-intensive, regimens, increasingly implemented during the pandemic, to minimize patient exposure and reduce usage of hospital beds, appeared to be associated with a low incidence of COVID-19. Further follow-up will be required to understand the long-term impact of this strategy. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program
  17. 1551677
    “…None of the other patient characteristics, which included: gender, ethnicity, age, BMI, smoking, obesity, chronic kidney disease, diabetes mellitus, hypertension, coronary vascular disease, and lung disease, were associated with significantly increased rate of hospitalization. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience
  18. 1551678
    “…Background: SARS-CoV-2 related acute respiratory distress syndrome (ARDS) is associated with endothelial dysfunction and profound dysregulation of the thrombotic/fibrinolytic pathway, with thrombotic complications common in affected patients (pts). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome
  19. 1551679
    por Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Cross, William, Jones, Robert J, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Amos, Claire L, Atako, Nafisah, Pugh, Cheryl, Buckner, Michelle, Chowdhury, Simon, Malik, Zafar, Russell, J Martin, Gilson, Clare, Rush, Hannah, Bowen, Jo, Lydon, Anna, Pedley, Ian, O'Sullivan, Joe M, Birtle, Alison, Gale, Joanna, Srihari, Narayanan, Thomas, Carys, Tanguay, Jacob, Wagstaff, John, Das, Prantik, Gray, Emma, Alzoueb, Mymoona, Parikh, Omi, Robinson, Angus, Syndikus, Isabel, Wylie, James, Zarkar, Anjali, Thalmann, George, de Bono, Johann S, Dearnaley, David P, Mason, Malcolm D, Gilbert, Duncan, Langley, Ruth E, Millman, Robin, Matheson, David, Sydes, Matthew R, Brown, Louise C, Parmar, Mahesh K B, James, Nicholas D
    Publicado 2022
    “…INTERPRETATION: Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
  20. 1551680
    “…Her worsening condition as well as its associated complications related to treatment and polypharmacy have significantly affected her mental health and quality of life in many ways, including suffering from depression and fatigue. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    O07 Managing relapsing and refractory lupus nephritis in juvenile systemic lupus erythematosus: a case report
Herramientas de búsqueda: RSS